American Journal of Perinatology Publishes Results of Group B Streptococcus Research Using NanoLogix, Inc. Biotechnology

HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today that the American Journal of Perinatology has published a peer-reviewed paper from the University of Texas Health Science Center - Houston confirming NanoLogix BioNanoPore (BNP) and BioNanoFilter (BNF) Quick Test technology detect and identify Group B Strep in four to six hours. The published results are in stark contrast to current Petri culturing or PCR Protocol (DNA sequencing) methods. While those conventional methods require between 48 to 72 hours of incubation to obtain results, the NanoLogix diagnostic technology for Group B Strep has proven to be 12 to 18 times faster.